New drugs in gynecologic cancer

被引：4
作者：
Daud A. [1 ]
Munster P. [1 ]
Spriggs D.R. [1 ]
机构：
[1] Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10021, NY
来源：
Current Treatment Options in Oncology | 2001年 / 2卷 / 2期
关键词：
CDDP; Epothilone; Oxaliplatin; Paclitaxel; Ubiquitin Proteasome System;
D O I：
10.1007/s11864-001-0054-0
中图分类号：
学科分类号：
摘要：
The implementation of new drug treatments has improved the prognosis for advanced cancers of the cervix, uterus, and ovary. Platinum analogs are the most effective drugs in the treatment of ovarian cancer. Other drugs, such as oxaliplatin, have been proposed as a rational treatment of platinum refractory ovarian cancer. Epothilones are also being studied in clinical trials, as are histone deacetylase inhibitors. Several promising agents may soon receive Food and Drug Administration approval. © 2001, Current Science Inc.
引用
收藏
页码：119 / 128
页数：9
相关论文
共 34 条
  • [1] Fink D., N∄bel S., Aebi S., Et al., The role of mismatch repair in acquired platinum drug resistance, Cancer Res, 56, pp. 4881-4886, (1996)
  • [2] Vaisman A., Varechenco M., Umar A., Et al., The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxalipatin resistance: correlation with replicative bypass of platinum-DNA adducts, Cancer Res, 58, pp. 3579-3585, (1998)
  • [3] Sessa C., ten B.H.W.W., du B.A., Oxaliplatin in ovarian cancer, Ann Oncol, 10, pp. S55-S57, (1999)
  • [4] Piccart M.J., Green J.A., Lacave A.J., Et al., Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group, J Clin Oncol, 18, pp. 1193-1202, (2000)
  • [5] Holford J., Sharp S.Y., Murrer B.A., Et al., In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473, Br J Cancer, 77, pp. 366-373, (1998)
  • [6] Raynaud F.I., Boxall F.E., Goddard P.M., Et al., Cis Amminedichloro(2methylpyridine) Platinum (II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology and pharmacokinetics in mice, Clin Cancer Res, 3, pp. 2063-2074, (1997)
  • [7] Trigo J.M., Beale P., Judson I.R., (1999)
  • [8] Manzotti C., Pratesi G., Menta E., Et al., BBR 3464— a novel triplatinum complex exhibiting a preclinical profile of antitumor efficacy different from cisplatin, Clin Cancer Res, 6, pp. 2626-2634, (2000)
  • [9] Sharp S.Y., Kelland L.R., BBR-3464, Current Opinion in Oncologic, Endocrine and Metabolic Investigational Drugs, 2, pp. 353-360, (2000)
  • [10] Pratesi G., Perego P., Polizzi D., Et al., A novel charged trinuclear platinum complex effective against cisplatin resistant tumors: hypersensitivity of p53 mutant human tumors xenografts, Br J Cancer, 80, pp. 1912-1919, (1999)
1234